LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Stock List・Agios Pharmaceuticals Inc

Agios Pharmaceuticals Inc

Open

SectorHealthcare

27.98 -2.44

Buy Sell

Overview

Share price change

24h

Current

Min

27.73

Max

28.77

Key metrics
By Trading Economics
Income	8.9M -99M
Sales	779K 21M
P/E Sector Avg	3.836 51.415
EPS	-1.69
Profit margin	-477.735
Employees	539
EBITDA	12M -109M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+36.95% upside

Dividends
By Dow Jones
Next Earnings	30 Jul 2026

Market Stats
By TradingEconomics
Market Cap	212M 1.7B
Previous open	30.42
Previous close	27.98

News Sentiment

By Acuity

34%

66%

96 / 346 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

28.04 / 30.06 Support & Resistance

Agios Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

19 Nov 2025, 15:05 UTC

Earnings

Acquisitions, Mergers, Takeovers

These Stocks Are Moving the Most Today: Nvidia, Lowe's, Target, Semrush, MP Materials, Plug Power, Dycom, and More -- Barrons.com

Peer Comparison

Price change

Agios Pharmaceuticals Inc Forecast

Price Target

By TipRanks

36.95% upside

12 Months Forecast

Average 39.4 USD 36.95%

High 50 USD

Low 28 USD

Based on 8 Wall Street analysts offering 12 month price targets forAgios Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Agios Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

28.04 / 30.06Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

The bullish and bearish events are balanced.

Sentiment

By Acuity

96 / 346 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Agios Pharmaceuticals Inc

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.